Lantern Pharma (LTRN) Liabilities and Shareholders Equity (2019 - 2026)

Lantern Pharma (LTRN) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $7.2 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 65.76% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.3 million (down 56.19% YoY) and the FY2025 annual result came in at $11.0 million, down 56.84% from the prior year.
• Liabilities and Shareholders Equity slipped to $7.2 million in Q1 2026, from $11.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $68.4 million in Q1 2022 to a low of $7.2 million in Q1 2026.
• A 5-year average of $38.6 million and a median of $39.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity retreated 17.09% — and 2026, when it slumped 65.76%.
• Tracing LTRN's Liabilities and Shareholders Equity over 5 years: stood at $58.8 million in 2022, then declined by 25.82% to $43.6 million in 2023, then tumbled by 41.41% to $25.6 million in 2024, then sank by 56.84% to $11.0 million in 2025, then slumped by 34.55% to $7.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.2 million (Q1 2026), $11.0 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.